For help on how to get the results you want, see our search tips.
2 results
Medicine type
Orphan medicine Remove Orphan medicine filter
Additional monitoring Remove Additional monitoring filter
Biosimilar Remove Biosimilar filter
Conditional approval Remove Conditional approval filter
Generic Remove Generic filter
Medicine
Referrals Remove Referrals filter
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Referral safety status
Yes Remove Yes filter
Categories
Human Remove Human filter
Referral PRAC recommendation
Risk minimisation measures Remove Risk minimisation measures filter
-
List item
Referral: Janus kinase inhibitors (JAKi)
tofacitinib, abrocitinib, baricitinib, upadacitinib, filgotinib, associated names: Xeljanz, Cibinqo, Olumiant, Rinvoq, Jyseleca, Article 20 procedures
Status: European Commission final decision, opinion/position date: 23/01/2023, EC decision date: 10/03/2023, Last updated: 22/05/2023 -
List item
Referral: Lemtrada
alemtuzumab, associated names: Lemtrada, Article 20 procedures
Status: European Commission final decision, opinion/position date: 14/11/2019, EC decision date: 16/01/2020, Last updated: 04/02/2020